The Pilot Advance Market Commitment for Vaccines Tania Cernuschi Senior Manager, AMC GAVI Alliance Marketplace on Innovative.

Slides:



Advertisements
Similar presentations
Advance Market Commitment Concept & Development Tania Cernuschi Senior Manager, AMC Copenhagen, 26 August 2009 AMC Pneumo Pre-tender Meeting.
Advertisements

Conflict Affected and Fragile States Facility (CAF) Environmental and Social Challenges Trust Fund Two new Facilities: WBG Donor Forum – Paris – May 19,
The Effectiveness of Global Health Partnerships Findings and Lessons from a World Bank Evaluation of Global Health Programs Uma Lele April 14, 2005.
Pricing Decisions and Cost Management
Pricing Decisions and Cost Management
Critical conversations in Public-private partnerships Dr Ranjana Kumar 1 st November 2007.
Procurement of Pneumococcal Vaccines under the Advance Market Commitment Pre Tender Meeting UNICEF Supply Division, 10-11th December 2008 Ann Ottosen.
Advance Market Commitments for Vaccines Carlo Monticelli International Financial Relations Ministero dell’Economia e delle Finanze.
Mechanisms for “Better Money” in Financing & Procurement of Reproductive Health Supplies Update Fall 2006 Meeting of the Reproductive Health Supplies Coalition.
MANAGEMENT ACCOUNTING
General scientific/technical certainty
1 A Review of Potential Gains from Reforms ECRA Workshop 6 November 2006 Dr Brian Wharmby Independent Consultant, former Technical Director of Ofgem
© 2013 Cengage Learning. All Rights Reserved. May not be scanned, copied, duplicated, or posted to a publicly accessible website, in whole or in part.
Financing Access to Basic Utilities for All Mobilizing Finance: Zambian Experience Sam Gonga DTF.
Generation Expansion Daniel Kirschen 1 © 2011 D. Kirschen and the University of Washington.
Financing Urban Public Infrastructure
Tania Cernuschi AMC Secretariat GAVI Alliance The Advance Market Commitment Innovative Finance for Development The Advance Market Commitment Innovative.
Measles Partnership Meeting Yalda Momeni September 23 rd - WDC.
Chapter 9 Pricing.
Instruments of Financial Markets at Studienzentrum Genrzensee Switzerland. August 30-September 17, 2004 Course attended by: Muhammad Arif Senior Joint.
Total health ODA commitments, US$ Billions.
CH 1. Factors accounting for the growth of importance in the health sector  Global health and longevity gains  Expansion of health sector throughout.
Partnerships in Promoting Innovation and Managing Risk Scientific and Financial Innovation in AIDS Vaccines International AIDS Vaccine Initiative Labeeb.
BSP Contraceptive Initiative To broaden sustainable access to quality hormonal contraceptives through a new commercial venture Reproductive Health Supplies.
11 A Conversation with Our Grantees Water, Sanitation & Hygiene Initiative Bill & Melinda Gates Foundation 5 th World Water Forum Istanbul, Turkey March.
DR. IBRAHEM AL-EZZEE-FIN421CHAPTER1 1 Chapter 1 Long-Term Investing and Financial Decisions.
Projects and procurement (lecture). Procurement Acquiring hardware, software, materials, services, spare parts, skills, workforce etc. which are necessary.
Infrastructure Consortium Meeting June IFF for Immunziation Andrew Jones Senior Programme Officer, Innovative Financing.
Introduction to Business 3e 16 Part VI: Financial Management Copyright © 2004 South-Western. All rights reserved. FinancingFinancing.
Some considerations for an AMC in the climate context.
DRAFT V1 National Vaccine Supply Chain Innovations: Country Commitment to Ownership, Sustainability & Impact GAVI Partners’ Forum WHO – UNICEF – GAVI -
Innovative Financing for ICT4D The Case of TARAhaat.
Copyright © 2006 by Applied Strategies Consulting. All rights reserved. Applied Strategies Consulting 400 S El Camino Real, Suite 375 San Mateo, CA
ANALYSIS OF CORPORATE STRATEGY China Resources Enterprise.
Incentives for Innovation (Push and Pull) Andrew Alexandra Director Australian Research Council Special Research Centre for Applied Philosophy and Public.
Dairying in Asia: Strategic opportunities, challenges and the response Vinod Ahuja Livestock Policy Officer Food and Agriculture Organization of the UN.
Money and Capital Markets 25 C h a p t e r Eighth Edition Financial Institutions and Instruments in a Global Marketplace Peter S. Rose McGraw Hill / IrwinSlides.
Public Private Partnerships (PPPs) and The World Bank
33 Monetary Policy McGraw-Hill/Irwin Copyright © 2012 by The McGraw-Hill Companies, Inc. All rights reserved. 15.
Conceptual Tools The creation of new and improved financial products through innovative design or repackaging of existing financial instruments. Financial.
Social Biz Nuts and Bolts Environment Analysis General / External / Internal.
Igniting Markets for Sanitation Created by: Tamara Baker Cordell Jacks Danielle Pedi.
How can I make a profit and still run out of cash? Review Financial Statements Cash Flow and Working Capital.
AMC Governance and Institutional Support. Objectives Build on existing capacity Ensure appropriate independence and credibility through transparency,
Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.
Clean Energy Mini-Grids A UNEP Perspective 1 Mark Radka Chief, Energy Branch 7 March 2013.
Patents, Prizes, AMCs and CAMCs Aidan Hollis University of Calgary October 2007.
IFC AT A GLANCE FINANCE OPPORTUNITIES FOR THE PRIVATE SECTOR.
Can we achieve rotavirus vaccine immunization worldwide by 202X? Global Vaccines 202X: Access, Equity, Ethics May 3, 2011.
Chapter 16 Managing Costs and Uncertainty Cost Accounting Foundations and Evolutions Kinney and Raiborn Seventh Edition COPYRIGHT © 2009 South-Western,
Research and Innovation Research and Innovation SME support under HORIZON Dr Bernd Reichert Unit "Small and Medium-Sized Enterprises" DG Research.
Pneumococcal Vaccine Use Around the World: Successes and Challenges Adam L. Cohen, MD MPH Respiratory Diseases Branch, Division of Bacterial Diseases Centers.
1 Innovations in Global Vaccine Financing Amie Batson Health, Nutrition, Population The World Bank.
Pricing Strategy. Price strategy One of the four major elements of the marketing mix is price. Pricing is an important strategic issue because it is related.
The foreign exchange market ( currency, forex, or FX ) trades currencies. It lets banks and other institutions easily buy and sell currencies.
R. V. Verma National Housing Bank India
Copyright © 2007 McGraw-Hill Ryerson Limited
Innovative Financing Mechanisms
Pricing Decisions and Cost Management
Investment Alternatives
Chapter 6: Estimating demand and revenue relationships
Generation Expansion Daniel Kirschen
COMMERCILIZATION ISSUES AND CHALLANGES
Dairying in Asia: Strategic opportunities, challenges and the response
Projects and procurement
Investment Alternatives
Projects and procurement
Pricing Decisions and Cost Management
Multi*COINS IN COINS WE TRUST
The U.S. International Development Finance Corporation (the “DFC”)
Presentation transcript:

The Pilot Advance Market Commitment for Vaccines Tania Cernuschi Senior Manager, AMC GAVI Alliance Marketplace on Innovative Financial Solutions for Development Paris, March

Policy instrument (forward commitment) creating a viable market for a product (more lucrative and/or more certain) Pulls: commercial investment in R&D (innovation) or in manufacturing capacity for target product Aim: diffusion of new/existing technologies What is an AMC?

The Pilot AMC Problem

Market for vaccines in low income countries Few suppliers equilibrium, limited competition: high investment costs, high risk High and indivisible capital investment costs: capacity decisions early in the process, cannot easily expand Perceived demand risk Companies do not generally take developing country demand into account when choosing vaccines to develop or when making decision on production capacity

Commercial Investment for Neglected Diseases  Investment for R&D to prevent/cure diseases primarily affecting poor countries is limited: $2.5 billion in 2007  Many needed vaccines are not developed  Existing vaccines do not meet developing countries’ needs for formulation, presentation, storage, and packaging  Existing vaccines are not available in enough quantities to meet demand from developing countries  Lag of years between the introduction of new vaccines in developed and in developing countries Source: G Finder Report 2008, the George Institute for International Health Little commercial investment to complement public resources

The Pilot AMC Solution

AMC for vaccines 7 Predictable & lower prices Predictable & growing demand Predictable & growing supply 1.Ensures sufficient/predictable returns on investment - increased capacity for developing countries (or R&D) 2.Accelerates price decline & enhances prices predictability for recipients 3.Leads to predictable & growing demand

8 Pneumo AMC Structure Binding commitment by donors (AMC Offer: $1.5 billion) to support purchase of target vaccines for poor countries Main features: Price guarantee up to a fixed number of vaccines – Guaranteed co-payments by AMC sponsors to top-up the price of vaccines paid by countries (and/or international agencies) An obligation on the producer to sell further vaccines in target countries at an affordable price Vaccines must meet as target product profile Vaccines must be demanded by developing countries Offer is to all manufacturers who compete to access funds

Pneumococcus  High disease burden - High demand: 200M doses per year at peak  Pneumo vaccines are likely to fit into existing delivery systems  Limits of available health interventions  Relatively easy to specify target product profile 9

Pilot: Results & Challenges

Results 11  High interest from manufacturers  If introduction in 2010, time-lag between developed and developing countries intro reduced to few months  Price decline: $4.25 (average) per dose compared to $71 in U.S.  Cost effective health intervention: $33-36 per DALY, compared to $100 benchmark  Planned evaluations  Too early to determine success – several years required to observe development of new vaccines, increased supply availability, accelerated uptake  Process/Design evaluation 2011  Impact evaluation every 4 years starting 2014

Challenges 12  Difficulty in establishing prices and size of AMC: asymmetric info between companies and public sector funders; complex to estimate costs when product does not yet exist;  Demand risk: GAVI requires new and multi-year predictable support to purchase pneumo vaccines  The AMC as part of the solution: IP, market segmentation for differential pricing  Very long time horizon – inflation, serotype replacement etc.  Politics/Public perceptions - Subsidizing private sector (big pharma)  Financial structure - Upfront legally binding commitments, long-term payment arrangements  Trade-off between objectives: development of new vaccines and increased supply